drugset / Trial / NCT00437242

Odiparcil QT Definitive Study

NCT00437242

Phase 1 Terminated 54 enrolled GlaxoSmithKline
RandomizedCrossoverDouble-blindTreatment

Summary

This study is being completed to demonstrate the lack of effect of repeat dosing with Odiparcil on the QTc interval.

Timeline

Start
2006-10
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Odiparcil Small molecule Oral

Indications